| Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial O Hermine, X Mariette, PL Tharaux, M Resche-Rigon, R Porcher, ... JAMA internal medicine 181 (1), 32-40, 2021 | 907 | 2021 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 488 | 2021 |
| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet infectious diseases 22 (2), 209-221, 2022 | 370 | 2022 |
| Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure MB Zeisel, J Lucifora, WS Mason, C Sureau, J Beck, M Levrero, M Kann, ... Gut 64 (8), 1314-1326, 2015 | 314 | 2015 |
| Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19 T Hueso, C Pouderoux, H Péré, AL Beaumont, LA Raillon, F Ader, ... Blood, The Journal of the American Society of Hematology 136 (20), 2290-2295, 2020 | 288 | 2020 |
| Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial PL Tharaux, G Pialoux, A Pavot, X Mariette, O Hermine, M Resche-Rigon, ... The Lancet Respiratory Medicine 9 (3), 295-304, 2021 | 284 | 2021 |
| Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses H Pan, R Peto, AMH Restrepo, MP Preziosi, V Sathiyamoorthy, QA Karim, ... The Lancet 399 (10339), 1941-1953, 2022 | 258 | 2022 |
| Campylobacter Bacteremia: Clinical Features and Factors Associated with Fatal Outcome J Pacanowski, V Lalande, K Lacombe, C Boudraa, P Lesprit, P Legrand, ... Clinical Infectious Diseases 47 (6), 790-796, 2008 | 257 | 2008 |
| HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe P Ingiliz, TC Martin, A Rodger, HJ Stellbrink, S Mauss, C Boesecke, ... Journal of hepatology 66 (2), 282-287, 2017 | 209 | 2017 |
| Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how? P Tiberghien, X de Lamballerie, P Morel, P Gallian, K Lacombe, ... Vox sanguinis 115 (6), 488-494, 2020 | 206 | 2020 |
| HIV and viral hepatitis coinfections: advances and challenges K Lacombe, J Rockstroh Gut 61 (Suppl 1), i47-i58, 2012 | 199 | 2012 |
| 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0 L Ryom, A Cotter, R De Miguel, C Béguelin, D Podlekareva, JR Arribas, ... HIV medicine 21 (10), 617-624, 2020 | 169 | 2020 |
| Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach M Lemoine, S Eholié, K Lacombe Journal of hepatology 62 (2), 469-476, 2015 | 167 | 2015 |
| Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study JK Rockstroh, K Lacombe, RM Viani, C Orkin, D Wyles, AF Luetkemeyer, ... Clinical Infectious Diseases 67 (7), 1010-1017, 2018 | 159 | 2018 |
| Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV K Lacombe, V Massari, PM Girard, L Serfaty, J Gozlan, G Pialoux, ... Aids 20 (3), 419-427, 2006 | 147 | 2006 |
| Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy R Duléry, S Lamure, M Delord, R Di Blasi, A Chauchet, T Hueso, C Rossi, ... American journal of hematology 96 (8), 934-944, 2021 | 126 | 2021 |
| Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients A Boyd, K Lacombe, F Lavocat, S Maylin, P Miailhes, C Lascoux-Combe, ... Journal of hepatology 65 (4), 683-691, 2016 | 124 | 2016 |
| Long-term hepatitis B virus dynamics in HIV–hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate K Lacombe, J Gozlan, PY Boelle, L Serfaty, F Zoulim, AJ Valleron, ... Aids 19 (9), 907-915, 2005 | 118 | 2005 |
| Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study K Champenois, A Cousien, L Cuzin, S Le Vu, S Deuffic-Burban, E Lanoy, ... BMC infectious diseases 13, 1-10, 2013 | 117 | 2013 |
| An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 F Ader, N Peiffer-Smadja, J Poissy, M Bouscambert-Duchamp, D Belhadi, ... Clinical Microbiology and Infection 27 (12), 1826-1837, 2021 | 106 | 2021 |
Anders BoydGGD Amsterdam, Stichting HIV Monitoring在 amsterdamumc.nl 的电子邮件经过验证
